Elranatamab

Description

This is an investigational humanized IgG2 BsAb that designed to bind to BCMA, which is highly expressed on the surface of multiple myeloma (MM) cells, and the CD3 receptor found on the surface of T-cells, bridging them together and activating the T-cells to kill the myeloma cells. The binding affinities of elranatamab for BCMA and CD3 have been engineered to elicit potent T-cell-mediated anti-myeloma activity. The agent is an alternative to intravenous administration, and may reduce the risk of potential adverse effects, such as cytokine release syndrome (CRS).

Contact Us for a Quote!

Please enable JavaScript in your browser to complete this form.
Name

Data Gallery

Fig. 1.) 4-20% SDS-PAGE analysis
Recombinant protein was visualized by Coomassie Brilliant Blue R250 staining.

Fig. 2.)    SEC-HPLC analysis
Column: Superdex 200 Increase 5/150 GL
Running buffer: 2xPBS, pH 7.4